RU2011144624A - PHARMACEUTICAL AEROSOL COMPOSITION OF PROTEAZ INHIBITORS WITH OZONE-SAVING PROPELLANT AND ITS PRODUCTION - Google Patents
PHARMACEUTICAL AEROSOL COMPOSITION OF PROTEAZ INHIBITORS WITH OZONE-SAVING PROPELLANT AND ITS PRODUCTION Download PDFInfo
- Publication number
- RU2011144624A RU2011144624A RU2011144624/15A RU2011144624A RU2011144624A RU 2011144624 A RU2011144624 A RU 2011144624A RU 2011144624/15 A RU2011144624/15 A RU 2011144624/15A RU 2011144624 A RU2011144624 A RU 2011144624A RU 2011144624 A RU2011144624 A RU 2011144624A
- Authority
- RU
- Russia
- Prior art keywords
- group
- propellant
- mixture according
- protease inhibitor
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 20
- 239000003380 propellant Substances 0.000 title claims abstract 9
- 239000008249 pharmaceutical aerosol Substances 0.000 title claims abstract 5
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract 8
- 239000013543 active substance Substances 0.000 claims abstract 6
- 239000000443 aerosol Substances 0.000 claims abstract 5
- 108010039627 Aprotinin Proteins 0.000 claims abstract 4
- 229960004405 aprotinin Drugs 0.000 claims abstract 4
- 239000007864 aqueous solution Substances 0.000 claims abstract 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims abstract 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims abstract 4
- 239000000654 additive Substances 0.000 claims abstract 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract 2
- 101710081722 Antitrypsin Proteins 0.000 claims abstract 2
- 102000015833 Cystatin Human genes 0.000 claims abstract 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract 2
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract 2
- 102000015636 Oligopeptides Human genes 0.000 claims abstract 2
- 108010038807 Oligopeptides Proteins 0.000 claims abstract 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims abstract 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims abstract 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims abstract 2
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims abstract 2
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims abstract 2
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 230000001475 anti-trypsic effect Effects 0.000 claims abstract 2
- 239000008346 aqueous phase Substances 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 108050004038 cystatin Proteins 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- 239000004615 ingredient Substances 0.000 claims abstract 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims abstract 2
- 229940041616 menthol Drugs 0.000 claims abstract 2
- 239000003921 oil Substances 0.000 claims abstract 2
- 235000019198 oils Nutrition 0.000 claims abstract 2
- 235000019477 peppermint oil Nutrition 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 2
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims abstract 2
- 238000005507 spraying Methods 0.000 claims abstract 2
- 239000002753 trypsin inhibitor Substances 0.000 claims abstract 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract 2
- 239000008158 vegetable oil Substances 0.000 claims abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- -1 aprotinin Chemical compound 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Фармацевтический аэрозольный состав ингибитора протеаз с озонсберегающим пропеллентом, отличающийся тем, что водный раствор активного вещества из группы ингибиторов протеаз, содержащий 0,05-250 мг протеазного ингибитора на мл раствора, последовательно смешивают с ингредиентами трех-компонентной выталкивающей смеси, а именно: глицерола, этанола и водонерастворимого озонсберегающего пропеллента с соотношением водной фазы и трехкомпонентной смеси 0,5-5 и 95-99,5 об.%, соответственно, и создают гомогенный аэрозольный состав, позволяющий генерировать фармацевтический аэрозоль активного протеазного ингибитора за счет выталкивающей силы пропеллента при распылении полученного состава из аэрозольного устройства, снабженного выпускным клапаном.2. Смесь по п.1, отличающаяся тем, что водный раствор ингибитора протеаз последовательно смешивают с компонентами выталкивающей системы - глицеролом, этанолом и фтор-содержащим пропеллентом 134А, взятых в объемном соотношении 1-7:3-13:80-96%, соответственно.3. Смесь по п.1, отличающаяся тем, что активное вещество, выбранное из группы ингибиторов протеаз белковой и полипептидной природы, представлено апротинином, α 2-антиплазмином, α-1антитрипсином, антитрипсином, цистатином, преимущественно апротинином, или их комбинацией.4. Смесь по п.1, отличающаяся тем, что активное вещество выбрано из группы антипротеазных олигопептидов, состоящих из двух и более аминокислотных остатков и их модифицированных производных.5. Смесь по п.1, содержащая одну или несколько органолептических добавок, из группы растительных масел, включающей масло мяты перечной, мяты душистой, ментоловое масло в количестве 1. The pharmaceutical aerosol composition of the protease inhibitor with ozone-saving propellant, characterized in that an aqueous solution of the active substance from the group of protease inhibitors containing 0.05-250 mg of the protease inhibitor per ml of solution is sequentially mixed with the ingredients of a three-component push mixture, namely: glycerol, ethanol and a water-insoluble ozone-saving propellant with a ratio of the aqueous phase and a three-component mixture of 0.5-5 and 95-99.5 vol.%, respectively, and create a homogeneous aerosol composition that allows generating pharmaceutical aerosol of the active protease inhibitor due to the buoyancy of the propellant when spraying the resulting composition from an aerosol device equipped with an exhaust valve. 2. The mixture according to claim 1, characterized in that the aqueous solution of the protease inhibitor is sequentially mixed with components of the ejection system - glycerol, ethanol and a fluorine-containing propellant 134A, taken in a volume ratio of 1-7: 3-13: 80-96%, respectively. 3. A mixture according to claim 1, characterized in that the active substance selected from the group of protease inhibitors of protein and polypeptide nature is aprotinin, α 2-antiplasmin, α-1 antitrypsin, antitrypsin, cystatin, mainly aprotinin, or a combination thereof. A mixture according to claim 1, characterized in that the active substance is selected from the group of antiprotease oligopeptides consisting of two or more amino acid residues and their modified derivatives. The mixture according to claim 1, containing one or more organoleptic additives, from the group of vegetable oils, including peppermint oil, aromatic mint, menthol oil in an amount
Claims (7)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011144624A RU2657523C2 (en) | 2011-11-03 | 2011-11-03 | Pharmaceutical aerosol composition of protease inhibitors with ozone-preserving propellant and its preparation |
| EA201201362A EA034991B1 (en) | 2011-11-03 | 2012-10-27 | Pharmaceutical aerosol formulation of a protease inhibitor |
| PCT/RU2012/000896 WO2013066214A2 (en) | 2011-11-03 | 2012-11-01 | Aerosol pharmaceutical composition of protease inhibitors and production thereof |
| GB1409877.6A GB2511011A (en) | 2011-11-03 | 2012-11-01 | Aerosol pharmaceutical composition of protease inhibitors and production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2011144624A RU2657523C2 (en) | 2011-11-03 | 2011-11-03 | Pharmaceutical aerosol composition of protease inhibitors with ozone-preserving propellant and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2011144624A true RU2011144624A (en) | 2013-05-10 |
| RU2657523C2 RU2657523C2 (en) | 2018-06-14 |
Family
ID=48192963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011144624A RU2657523C2 (en) | 2011-11-03 | 2011-11-03 | Pharmaceutical aerosol composition of protease inhibitors with ozone-preserving propellant and its preparation |
Country Status (4)
| Country | Link |
|---|---|
| EA (1) | EA034991B1 (en) |
| GB (1) | GB2511011A (en) |
| RU (1) | RU2657523C2 (en) |
| WO (1) | WO2013066214A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2711080C2 (en) * | 2015-06-15 | 2020-01-15 | Олег Петрович Жирнов | Combined aerosol composition based on protease inhibitors and preparation thereof |
| US20240415944A1 (en) * | 2021-04-06 | 2024-12-19 | Andrey Alexandrovich Ivashchenko | Aqueous aprotinin-containing antiviral pharmaceutical composition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2656944B2 (en) * | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | Aerosolization of protein therapeutics |
| RU2054180C1 (en) * | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Method and aerosol for treating respiratory virus infections |
| US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| US6849263B2 (en) * | 1998-12-21 | 2005-02-01 | Generex Pharmaceutical Incorporated | Pharmaceutical compositions for buccal delivery of pain relief medications |
| US6294153B1 (en) * | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| EP1187639A1 (en) * | 1999-06-04 | 2002-03-20 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| WO2002043750A2 (en) * | 2000-12-01 | 2002-06-06 | Battelle Memorial Institute | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
| GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| RU2356537C2 (en) * | 2007-07-25 | 2009-05-27 | Закрытое Акционерное Общество (ЗАО) "Пульмомед" | Pharmaceutical composition of metered aerosols containing antiasthmatic agents in form of suspensions, solutions, emulsions, solutions and emulsions |
| RU2425691C1 (en) * | 2010-07-15 | 2011-08-10 | ВАКЕ спол с.р.о. | Aprotinin aerosol for treating viral respiratory infections |
-
2011
- 2011-11-03 RU RU2011144624A patent/RU2657523C2/en not_active Application Discontinuation
-
2012
- 2012-10-27 EA EA201201362A patent/EA034991B1/en not_active IP Right Cessation
- 2012-11-01 WO PCT/RU2012/000896 patent/WO2013066214A2/en not_active Ceased
- 2012-11-01 GB GB1409877.6A patent/GB2511011A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013066214A2 (en) | 2013-05-10 |
| RU2657523C2 (en) | 2018-06-14 |
| EA034991B1 (en) | 2020-04-15 |
| WO2013066214A3 (en) | 2013-08-22 |
| GB201409877D0 (en) | 2014-07-16 |
| EA201201362A1 (en) | 2013-05-30 |
| GB2511011A (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015122789A (en) | Aerosol composition with a propellant based on protease inhibitors and its preparation | |
| UA102477C2 (en) | Capsule composition | |
| AR076305A1 (en) | COMPOSITIONS OF ALFA- (N-SULFONAMIDE) COMPOSITE BIODISPONDS CAPSULES | |
| ES2625075T3 (en) | Aerosol compositions that eliminate odors and contain alkylene glycol (s) | |
| BRPI0910341A2 (en) | device for the conservation, spontaneous preparation and administration of an active ingredient | |
| AR051420A1 (en) | PROCESSES FOR THE PREPARATION OF OLEOUS COMPOSITIONS | |
| AR057697A1 (en) | SPRAY COMPOSITIONS | |
| RU2012144626A (en) | COMPOSITIONS AND METHODS USED FOR STABILIZING WHITE-CONTAINING READY FORMS | |
| RU2014147365A (en) | APPLICANT INJECTED COMPOSITIONS | |
| TsUKURA et al. | Effects of capsaicin on cellular damage and monolayer permeability in human intestinal Caco-2 cells | |
| RU2011144624A (en) | PHARMACEUTICAL AEROSOL COMPOSITION OF PROTEAZ INHIBITORS WITH OZONE-SAVING PROPELLANT AND ITS PRODUCTION | |
| EA201270745A1 (en) | IMPROVED STABLE AQUEOUS COMPOSITION (E) -4-CARBOXYSTYRYL-4-HLORBENZYLESULPHONE | |
| AR053977A1 (en) | PHARMACEUTICAL COMPOSITIONS WITH FLAVOR MASK | |
| CO6341531A2 (en) | FOOD ACID FOOD PRODUCT WITH CHIA BASE, RICH IN OMEGA-3, WITH GOOD STABILITY | |
| Gupta et al. | Preparation of prospective plant oil derived micro-emulsion vehicles for drug delivery | |
| AR084235A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ALISPORIVIR | |
| ES2497667T3 (en) | Emulsification system for use in cosmetics | |
| RU2013137782A (en) | WATER IONIC SOLUTION CONTAINING SEA WATER, AT LEAST ONE COMPOUND, NOT MIXED INITIATELY MIXED WITH SEA WATER | |
| MX2016008729A (en) | Pharmaceutical composition containing clomipramine and preparation method therefor. | |
| CN104367569A (en) | Nano coenzyme Q10 oral liquid | |
| ATE376834T1 (en) | COMPOSITION IN SPRAY FORM WITH A COMBINATION OF CLOBETASOL PROPIONATE AND CALCITRIOL, AN ALCOHOL PHASE AND OIL PHASE | |
| RU2013111743A (en) | NON-AQUATIC OIL INJECTION COMPOSITION MANIFESTING ANTISEPTIC EFFICIENCY | |
| US20140134124A1 (en) | Sanitary compound for use on skin | |
| JP5194337B2 (en) | Aerosol | |
| JP4997767B2 (en) | Ubidecarenone-containing composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150111 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20151118 |